CoChat

Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

Lewis, James H., Gelderblom, Hans, Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia-Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian · 2021 · The Oncologist
Cited by 58

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. Materials, and Methods: Hepatic adverse reactions (ARs) were assessed by type and magnitude of liver test abnormalities, classified as (a) isolated aminotransferase elevations (alanine [ALT] or aspartate [AST], without significant alkaline phosphatase [ALP] or bilirubin elevations), or (b) mixed or cholestatic hepatotoxicity (increase in ALP with or without ALT/AST and bilirubin elevations, based on adjudication). Median follow-up from initial pexidartinib treatment was 39 months (range, 32–82) in 140 patients with TGCTs across clinical studies NCT01004861, NCT02371369, NCT02734433, and NCT03291288. Results: In total, 95% of patients with TGCTs (133/140) treated with pexidartinib (median duration of exposure, 19 months [range, 1–76]), experienced a hepatic AR. A total of 128 patients (91%) had reversible, low-grade dose-dependent isolated AST/ALT elevations without significant ALP elevations. Five patients (4%) experienced serious mixed or cholestatic injury. No case met Hy's law criteria. Onset of hepatic ARs was predominantly in the first 2 months. All five serious hepatic AR cases recovered 1–7 months following pexidartinib discontinuation. Five patients from the non-TGCT population (N = 658) experienced serious hepatic ARs, two irreversible cases. Conclusion: This pooled analysis provides information to help form the basis for the treating physician's risk assessment for patients with TCGTs, a locally aggressive but typically nonmetastatic tumor. In particular, long-term treatment with pexidartinib has a predictable effect on hepatic aminotransferases and unpredictable risk of serious cholestatic or mixed liver injury. Implications for Practice: This is the first long-term pooled analysis to report on the long-term hepatic safety of pexidartinib in patients with tenosynovial giant cell tumors associated with severe morbidity or functional limitations and not amenable to improvement with surgery. These findings extend beyond what has been previously published, describing the observed instances of hepatic toxicity following pexidartinib treatment across the clinical development program. This information is highly relevant for medical oncologists and orthopedic oncologists and provides guidance for its proper use for appropriate patients within the Pexidartinib Risk Evaluation and Mitigation Safety program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/onco.13629

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 37

  1. Mastboom, 2019, Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: An international, retrospective, cohort study, Lancet Oncol, 20, 877, 10.1016/S1470-2045(19)30100-7 · DOI
  2. Saint Aubain Somerhausen, 2013, WHO Classification of Tumours of Soft Tissue and Bone, 100
  3. Staals, 2016, Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives, Eur J Cancer, 63, 34, 10.1016/j.ejca.2016.04.022 · DOI
  4. Mastboom, 2017, Limb amputation after multiple treatments of tenosynovial giant cell tumour: Series of 4 Dutch cases, Case Rep Orthop, 2017
  5. Tap, 2019, Multidisciplinary care in tenosynovial giant cell tumours, Lancet Oncol, 20, 755, 10.1016/S1470-2045(19)30173-1 · DOI
  6. Brahmi, 2016, Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: Targeting the CSF1/CSF1R axis, Curr Treat Options Oncol, 17, 10.1007/s11864-015-0385-x · DOI
  7. Cassier, 2015, CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study, Lancet Oncol, 16, 949, 10.1016/S1470-2045(15)00132-1 · DOI · Paper page
  8. Gelderblom, 2018, Nilotinib in locally advanced pigmented villonodular synovitis: A multicentre, open-label, single-arm, phase 2 trial, Lancet Oncol, 19, 639, 10.1016/S1470-2045(18)30143-8 · DOI
  9. Nakayama, 2018, Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy, BMC Cancer, 18, 10.1186/s12885-018-5188-6 · DOI
  10. Palmerini, 2015, Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors, Eur J Cancer, 51, 210, 10.1016/j.ejca.2014.11.001 · doi:10.1016/j.ejca.2014.11.001
  11. Ravi, 2011, Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis, Curr Opin Oncol, 23, 361, 10.1097/CCO.0b013e328347e1e3 · DOI · Paper page
  12. Rebuzzi, 2020, Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour, Anticancer Drugs, 31, 80, 10.1097/CAD.0000000000000844 · DOI
  13. Tap, 2019, Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial, Lancet, 394, 478, 10.1016/S0140-6736(19)30764-0 · DOI · Paper page
  14. Temple, 2012, Pigmented villonodular synovitis therapy with MSCF-1 inhibitors, Curr Opin Oncol, 24, 404, 10.1097/CCO.0b013e328354c16b · doi:10.1097/cco.0b013e328354c16b
  15. Verspoor, 2019, Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor, Sci Rep, 9, 10.1038/s41598-019-51211-y · DOI
  16. Turalio (pexidartinib) capsules, for oral use, 2020, Prescribing information
  17. NCCN, 2020, clinical practice guidelines in oncology: Soft tissue sarcoma—version 5.2019
  18. Shah, 2013, Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives, Drug Saf, 36, 491, 10.1007/s40264-013-0048-4 · DOI · Paper page
  19. Teo, 2013, Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis, Cancer Treat Rev, 39, 199, 10.1016/j.ctrv.2012.09.004 · DOI
  20. Teo, 2015, Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review, Expert Opin Drug Metab Toxicol, 11, 231, 10.1517/17425255.2015.983075 · DOI · Paper page
  21. Lee, 2020, A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors, Invest New Drugs, 38, 99, 10.1007/s10637-019-00745-z · DOI · Paper page
  22. U.S. Food and Drug Administration. FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting May 14, 2019, NDA 211810: Pexidartinib, 2019
  23. Regev, 2014, Drug-induced liver injury: Morbidity, mortality, and Hy's law, Gastroenterology, 147, 20, 10.1053/j.gastro.2014.05.027 · DOI
  24. Piawah, 2019, A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel, NPJ Breast Cancer, 5, 10.1038/s41523-019-0112-z · DOI
  25. Genovese, 2015, Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy, J Rheumatol, 42, 1752, 10.3899/jrheum.141580 · DOI · Paper page
  26. Pognan, 2019, Colony-stimulating factor-1 antibody lacnotuzumab in a phase 1 healthy volunteer study and mechanistic investigation of safety outcomes, J Pharmacol Exp Ther, 369, 428, 10.1124/jpet.118.254128 · DOI
  27. Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
  28. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  29. Lewis, 2014, Drug-induced liver injury, dosage, and drug disposition: Is idiosyncrasy really unpredictable?, Clin Gastroenterol Hepatol, 12, 1556, 10.1016/j.cgh.2014.02.011 · DOI
  30. Lewis, 2015, The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond, Clin Gastroenterol Hepatol, 13, 2173, 10.1016/j.cgh.2015.06.017 · DOI
  31. Huang, 2020, Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: A disproportionality analysis of FDA adverse event reporting system, Sci Rep, 10
  32. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  33. LiverTox, 2012, Clinical and research information on drug-induced liver injury
  34. Kim, 2018, Risk factors for erlotinib-induced hepatotoxicity: A retrospective follow-up study, BMC Cancer, 18, 10.1186/s12885-018-4891-7 · doi:10.1186/s12885-018-4891-7
  35. Desmet, 1992, Vanishing bile duct disorders, Prog Liver Dis, 10, 89
  36. Desmet, 1998, Histopathology of vanishing bile duct diseases, Adv Clin Path, 2, 87
  37. Visentin, 2018, Drug-induced bile duct injury, Biochim Biophys Acta Mol Basis Dis, 1864, 1498, 10.1016/j.bbadis.2017.08.033 · DOI

Cited by

See all 58

Metadata

Authors
Lewis, J. H., Gelderblom, H., Sande, M., Stacchiotti, S., Healey, J. H., Tap, W. D., Wagner, A. J., Pousa, A. L., Druta, M., Lin, C.-C., Baba, H. A., Choi, Y., Wang, Q., Shuster, D. E., & Bauer, S.
Affiliations
  • Georgetown University Hospital, Washington, District of Columbia, USA
  • Leiden University Medical Center, Leiden, The Netherlands
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  • Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
  • Moffitt Cancer Center, Tampa, Florida, USA
  • National Taiwan University Hospital, Taipei, Taiwan
  • University Hospital Essen, University of Duisburg-Essen, Germany
  • Daiichi Sankyo, Inc, Basking Ridge, New Jersey, USA
Venue
The Oncologist
Published
2020-12-24
Volume
26
Issue
5
Pages
e863-e873
ISSN
  • 1083-7159
  • 1549-490X
Cited by
58
References
3
Language
en
Funders
Daiichi Sankyo, Co., Ltd

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. https://app.cochat.ai/papers/10.1002/onco.13629
The paper
Lewis, J. H., Gelderblom, H., Sande, M., Stacchiotti, S., Healey, J. H., Tap, W. D., Wagner, A. J., Pousa, A. L., Druta, M., Lin, C.-C., Baba, H. A., Choi, Y., Wang, Q., Shuster, D. E., & Bauer, S. (2021). Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. The Oncologist. https://doi.org/10.1002/onco.13629

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.